Avery Therapeutics, Inc

Tucson, AZ · Founded 2015 · CIK 0001708135 · Biotech · Private

Tissue engineered cardiac muscle therapeutics for heart failure treatment

averythera.com →
Grants
$1.1M
3 awards
Sector median: 1
Raised
$9.0M
2 Form D · Sep 2026
1 months since last filing
Contracts
—
No federal contracts on record
Patents
12
1 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · HLS16-07: Manufacturing Tissue Engineered Patch to Treat Heart Failure$483,960
Private capital raisedForm D · SEC$500,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Development and Assessment of an Engineered Cardiac Tissue for Treating Dilated Cardiomyopathy$299,998
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Development and Assessment of an Engineered Cardiac Tissue for Treating Dilated Cardiomyopathy$299,998
Private capital raisedForm D · SEC$8,468,859
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1533Akeso——
1534Ctrl Therapeutics——
1535Human Immunology Biosciences——
1536Avery Therapeutics, Inc—$9.0M
1537F2G——
1538Glyco Expression Technologies (Corporation)——
1539Purilogics, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Steven GoldmanExecutive Officer
  • Jennifer KoevaryExecutive Officer
  • Jordan LancasterExecutive Officer

Patents

USPTO · 1 granted of 12
  • Three Dimensional Tissue Compositions And Methods Of Useapplication
  • Three Dimensional Tissue Compositions And Methods Of Usegranted
  • Compositions And Methods For Cryopreservation And Reconstitution Of Engineered Tissuesapplication
  • Cell-free Compositions And Methods For Restoration Or Enhancement Of Tissue Functionapplication
  • Cell-free Compositions And Methods For Restoration Or Enhancement Of Tissue Functionapplication
  • Compositions And Methods For Cryopreservation And Reconstitution Of Engineered Tissuesapplication
  • Therapy For Tissue Regenerationapplication
  • Three Dimensional Tissue Compositions And Methods Of Useapplication
  • Three Dimensional Tissue Compositions And Methods Of Useapplication
  • Viable Cultured Cardiac Matrixapplication
  • Mycardia: A Viable Cultured Cardiac Matrixapplication
  • Compositions And Methods For Cryopreservation And Reconstitution Of Engineered Tissuesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.